The FDA has approved a supplemental application for Gardasil 9 (Human Papillomavirus (HPV) 9-valent Vaccine, Recombinant) expanding the approved use...
Sanofi Pasteur MSD announced that the European Commission has granted marketing authorization for Gardasil 9. Gardasil 9 is a 9-valent...
The FDA has approved Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant) from Merck Inc., for the prevention of certain diseases...
The FDA has approved an expanded age indication for Gardasil 9 (human papillomavirus 9-valent vaccine, recombinant), to now include use...
The European Committee for Medicinal Products for Human Use granted a positive opinion for Gardasil 9, from Sanofi Pasteur MSD,...
Merck Inc.,, announced results from final analyses of the pivotal Phase III efficacy, immunogenicity, and safety clinical trial for Gardasil...
Sanofi Pasteur MSD announced that the Summary of Product characteristics (SmPC) of Gardasil vaccine for Cervical Cancer has been updated...
Merck Inc., known as MSD outside of the United States and Canada, at the EUROGIN 2024 HPV Congress, announced plans to initiate clinical development of a new investigational multi-valent HPV vaccine designed to provide broader protection against multiple HPV types
Merck Inc., has announced that the FDA has accepted for review a new supplemental Biologics License Application (sBLA) for Gardasil...
Gardasil is a vaccine for use from the age of 9 years for the prevention of: – premalignant genital lesions (cervical, vulvar and vaginal), premalignant anal lesions, cervical cancers and anal cancers causally related to certain oncogenic Human Papillomavirus (HPV) types – genital warts (condyloma acuminata) causally related to specific HPV types. See sections 4.4 and 5.1 for important information on the data that support this indication. The use of Gardasil should be in accordance with official recommendations.